日期: 2025 年 12 月 15 日

香港, 2025年12月15日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK）發佈公司2030發展戰略。受戰略發佈提振，公司股價當日整體表現強勁，盤中一度觸及48.54港元的階段高點。截至當日收市，雲頂新耀股價報46.88港元，上漲4.55%，股價全天維持在相對高位運行，顯示市場反應積極。市場認為，當日股價的強勢表現，既反映了投資者對公司中長期戰略方向的認可，也與此前管理層及主要股東釋放的信心信號密切相關。此前於12月12日，雲頂新耀對外披露董事及主要股東增持公司股份的相關公告，多位管理層成員通過公開市場合計增持公司普通股846,659股，涉及總金額超過3,800萬港元；同時，主要股東康橋資本亦承諾將在未來三至六個月內，在視市場情況及符合法律監管要求的前提下，進一步增持公司股份。相關舉措被視為管理層及核心股東對公司長期發展前景的明確表態。雲頂新耀2030戰略明確提出以「BD合作+自研」雙輪驅動，實現商業化創造確定性價值、自研創造成長性價值。公司將持續鞏固核心治療領域優勢，推進創新藥研發和商業化，打造可持續增長的全球化創新型生物制藥企業。公司聚焦腎科、自身免疫、急重症、心血管及眼科等核心方向，通過引進創新資產與自主研發並行推進，到2030年形成高價值產品組合，並拓展其他藍海領域的大單品。商業化平台建設方面，公司已布局三款商業化產品，並著力建立全渠道商業化體系及藥品全生命周期商業化能力。到2030年，公司計劃實現收入規模超過150億元人民幣，其中現有管線銷售收入約90億元，新引進管線銷售收入約60億元，並探索潛在對外授權（License-out）收入；年複合增長率預計在2025-2030年超過50%，2030年後保持超過15%。同時，商業化產品數量將提升至20款以上，包括耐賦康®、維適平®、依嘉®、頭孢吡肟-他尼硼巴坦及樂瑞泊®（萊達西貝普）等。研發平台方面，公司以擁有全球權益的自研mRNA平台為基礎，持續推進現有管線，同時通過引進及生態孵化潛力平台拓展研發能力。到2030年，在核心平台mRNA in vivo CAR-T和mRNA腫瘤疫苗平台基礎上，擴展至其他高潛力平台（比如siRNA、抗體等），進一步強化核心治療領域研發實力。全球化能力建設方面，公司啟動全球化戰略，推進全球化的注冊及臨床開發能力建設，同時逐步自建歐美及新興市場商業化體系，盡快實現「海外授權+商業化」的雙引擎驅動增長，加快國際化發展步伐。值得一提的是，作為新橋生物的第一大股東（持股約16%）及重要戰略投資者，雲頂新耀還計劃與新橋生物深度協同，發掘優質資產，加強全球化研發能力建設，並通過創新藥商業化整合平台及「BD合作+自研」雙輪驅動模式，進一步拓展全球商業化及研發注冊能力。同時借助新橋生物在不限治療領域的全球化產業資源、團隊及頂尖人才，實現雙方優勢互補。雲頂新耀董事會榮譽主席、康橋資本首席執行官傅唯先生表示：「雲頂新耀發佈的2030戰略充分體現了公司在創新藥研發、商業化和全球化布局上的清晰規劃與前瞻性，展示了持續創造價值的能力。自2017年成立以來，公司通過授權引進（license-in）引入創新資產，建立了堅實的基礎，完成在香港交易所IPO，並依靠『雙輪』驅動戰略，聚焦藍海領域，打造卓越商業化平台並完善研發和生產能力，為公司未來發展奠定了堅實基礎。康橋資本將充分發揮全球產業資源和生態網絡優勢，與公司共享戰略與運營經驗，支持核心管線和研發平台的持續發展。作為主要股東，我們也通過增持股份進一步表達對公司長期發展前景的認可和支持。期待公司在未來持續引領創新藥研發與商業化發展，打造全球領先的綜合性生物制藥企業。」雲頂新耀董事會主席吳以芳先生強調：「2030戰略標志著雲頂新耀邁向全球生物制藥前沿的重要里程碑。未來五年，公司將聚焦『BD合作+自研』雙輪驅動，依托科學與市場洞察，推動戰略領域形成N+X產品組合，把握藍海大單品機遇。公司計劃通過已經建立的BD能力和康橋生態，每年引進3-5個中後期重磅產品，依托自身精幹高效的商業化團隊實現每個產品醫保後三年銷售達峰。未來五年，公司計劃引進20個以上的高值資產，為2030年貢獻收入60億，在2035年實現大約300億的收入貢獻。在自研方面，公司將持續推進創新藥自主研發平台建設，強化核心治療領域研發能力。同時，公司近期與海森生物簽署的商業化服務協議及授權許可協議，將充實後期管線布局、提升商業化平台運營效率，並助力心血管及相關領域業務拓展。未來，公司將持續推動管線拓展、商業化能力建設及全球研發佈局，不斷提升雲頂新耀在全球創新藥領域的綜合競爭力。在商業化現金流持續改善及充裕現金儲備的有力支撐下，公司將加快戰略落地，穩步邁向千億市值計劃的目標，為更多患者帶來高價值的創新治療選擇。」雲頂新耀首席執行官羅永慶先生表示：「通過深化『雙輪驅動』戰略，雲頂新耀正加速邁向全球領先的生物制藥公司。公司已建立以『科學及商業洞察驅動的醫學、准入、市場、銷售一體化協同』為核心的商業化體系，並持續強化平台能力建設，推動核心產品穩健增長。作為一款慢病用藥，耐賦康®在上市後的首個完整商業化年度，依靠不到200人的一線銷售團隊，今年前3季度銷售額已突破10億元成為行業最佳實踐之一，充分驗證了公司成熟且可複制的商業化能力。基於此，公司將把在腎科及抗感染領域積累的商業化體系與經驗，拓展至自身免疫、眼科、急重症及心血管等治療領域。科學及商業洞察也是研發的戰略出發點，我們將同時加速推進自研mRNA In vivo CAR-T平台及mRNA腫瘤疫苗平台的臨床開發進程。在2030戰略指引下，雲頂新耀將持續聚焦中國及全球尚未滿足的醫療需求，不斷提升全球創新藥競爭力，為更多患者帶來高價值創新治療選擇。」整體來看，雲頂新耀此次發佈的2030戰略，不僅系統規劃了未來發展的業務路徑，更通過管理層與主要股東的主動增持行動，體現了內外一致的戰略認同與長期信心。展望未來，在「雙輪驅動」戰略的持續引領下，雲頂新耀將繼續鞏固在核心治療領域和創新藥研發上的優勢，穩步邁向可持續增長的全球化生物制藥企業目標，成為全球領先的綜合性生物制藥公司。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

JAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - Indonesia's state-owned railway operator PT Kereta Api Indonesia (KAI) has rolled out two major initiatives aimed at strengthening national mobility and accelerating its digital shift: the launch of the Farmer and Trader Train on the Merak Commuter Line, and the expansion of face recognition boarding technology ahead of the 2025/2026 Christmas and New Year travel season.Farmer-Trader train to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.KAI said the programs reflect its commitment to inclusive transport services while enhancing operational efficiency and environmental performance — moves that align with international railway modernization trends.A special passenger train featuring oversized windows and often a large glass roof (sunroof) to provide unobstructed, wide-angle views of the passing scenery, turning the journey itself into a scenic experience."KAI is committed to building a rail ecosystem that supports grassroots economies while adopting technologies that meet global service standards," said KAI President Director Bobby Rasyidin. "These initiatives reinforce railways as an inclusive, efficient, and sustainable mode of public transport."New Farmer–Trader Train Strengthens Local Product DistributionEffective 1 December 2025, KAI began operating the Farmer and Trader Train on the Merak–Rangkasbitung corridor in Banten Province. The service is designed to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.The rolling stock was fully redesigned by Balai Yasa Surabaya Gubeng, KAI's technical workshop, which modified the interior layout, baggage sections, loading–unloading access points, and safety signage to meet the needs of micro and small enterprises."The train has been engineered by our in-house experts to ensure safe, orderly, and convenient goods movement without disrupting passenger flow," continued Rasyidin.The service operates under a government-funded Public Service Obligation (PSO) scheme with a flat fare of Rp3,000, allowing up to two cargo units per user. It is attached to 14 daily Commuter Line services and stops at 11 stations across coastal and agricultural areas.On launch day, 95 customers used the service, carrying agricultural produce, snacks, and handicrafts for markets in Serang, Cilegon, and Merak. KAI expects the service to reduce traders' reliance on road-based logistics and shift more local supply chains onto rail.Rasyidin said the initiative strengthens regional economic resilience: "Reliable logistics access for small producers is fundamental to local economies. This service opens a more predictable distribution channel for farmers and traders."Facial Recognition Technology Boosts Efficiency, Cuts WasteKAI is also expanding its facial recognition boarding system to improve passenger processing and reduce paper usage in major stations.KAI VP Public Relations Anne Purba, explains, between January and October 2025, the feature recorded 9.29 million uses, cutting ticket paper consumption by 23,245 rolls, equivalent to Rp341 million in savings. Since the system debuted in 2023, it has been used by 19.4 million passengers, contributing significantly to KAI's environmental and cost-reduction goals."Facial recognition shortens boarding time and significantly reduces paper waste, supporting more environmentally responsible operations," Purba said.The technology is now available in 22 stations, with wider deployment planned ahead of peak holiday travel to reduce queues and streamline passenger flow.Purba underscored the strategic value of automation: "Digitalization is not just innovation—it is increasingly essential to managing national mobility at scale. This system helps maintain operational stability when travel demand peaks."Holiday Ticket Sales Climb, Discounts ExpandedDemand for the year-end holiday period—18 December 2025 to 4 January 2026—continues to rise. As of 26 November, KAI had sold 629,060 tickets, or 21.15% of the roughly 3 million seats available.To support affordability and smooth travel, KAI is offering 30% discounts for 156 regular services and 26 additional economy-class trains, totaling 1.5 million discounted seats valid from 22 December to 10 January.Purba said higher mobility is expected across Java and Sumatra: "We are preparing large capacity and fare incentives to ensure safe, orderly, and accessible travel throughout the holiday season."Inclusive and Technology-Driven Mobility for IndonesiaBy combining inclusive rural-focused services with large-scale digital transformation, KAI aims to bring Indonesia's rail sector closer to global standards of accessibility, efficiency, and sustainability."Our strategy aligns with international efforts to build modern public transport systems that deliver broad social and economic impact," Purba concluded.For More Information, please contact:Anne PurbaVP Public RelationsPT Kereta Api Indonesia (Persero)Source: PT Kereta Api Indonesia (Persero), https://www.kai.id Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TransNusa Launched 11 International Routes in 3 YearsIndonesia-based PT TransNusa Mandiri Aviation grows a strong brand with expansion focusing on international routesTransNusa focuses on international tourism island destinations to offer domestic and foreign tourists increased air connectivityTransNusa introduces four new domestic scheduled direct flights to boost connectivity from Bali to Lombok and Bima as well as between renowned diving destinations Manado to Sorong and Sorong to Timika, world’s largest gold mining islandJAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - TransNusa has successfully launched four new domestic routes today, securing 19 routes in total within three years of operations.TransNusa Group CEO, aviation veteran, Datuk Bernard Francis, known for his acute, unique and out-of-the-box turnaround and change management strategies, led TransNusa towards a secure yet bold growth pattern using a customized business model, which was specifically developed to suit the changing market demand after the onslaught of the pandemic.“What we envisioned for TransNusa was to build an Indonesian-based airline with strong fundamentals. Today, thanks to our hard working and diligent team, the TransNusa brand has grown to resonates confidence and trust,” said Datuk Bernard, adding that TransNusa’s shareholder, China Aircraft Leasing Group Holdings Limited (CALC) and business partners also played a large role in helping build TransNusa into the strong brand it is today.Within 6 months of its operations, TransNusa launched its first international route between Jakarta and Kuala Lumpur, followed by three additional international routes in that same year, including Singapore and China.TransNusa also implemented a milestones as well as initiated and developed new domestic routes, such as the Bali-Manado route.In addition, TransNusa  the first Indonesian airline to operate regular scheduled international flights into Guanzhou from three destinations in Indonesia.Datuk Bernard said the primary factor in the successful growth of TransNusa, in the last three years, was their goal to implement a lasting and impactful change around not just the organisation and its people but also its business model and operations.“In TransNusa, a 100% change is not possible overnight, whereas a 5% change in a moderate manner is not only more feasible but allows for a lasting change,” said Datuk Bernard, explaining that it was that principal which has been the backbone of  TransNusa's operations and growth.On the new domestic route launches, Datuk Bernard said that TransNusa hopes to provide increased connectivity and travelling options to domestic and international tourists.“We would like to play our part in boosting and increasing air connectivity within Indonesia’s internationally renowned tourism island destinations.“Our focus is in increasing direct flight to destinations that are world renowned for its unique and stunning landscape and natural offerings,” said Datuk Bernard.DATUK BERNARD FRANCIS… TransNusa's team and business partners contributed to the growth of the airline and it’s brand.Flight DetailsTransNusa’s flight from Bali to Lombok will operate two times daily beginning Monday, December 15. The TransNusa flight will depart Bali from the Denpasar International Airport at 07.30am and arrive in Lombok International Airport at 07.55am, with the return flight departing Lombok at 08.25am and arriving in Bali at 09.05am. The second TransNusa flight will depart Bali at 15.55pm and arrive in Lombok at 16.50pm, with the return flight departing Lombok at 17.20pm and arriving in Bali at 18.05pm.“We will increase the frequency of the scheduled flights for the Bali-Lombok route to three times daily on December 21.” Said Datuk Bernard.The third scheduled flight will depart Bali at 18.55pm and arrive at Lombok at 19.35pm. The scheduled flight from Lombok will depart at 20.00pm and arrive in Bali at 20.25pm.Meanwhile, TransNusa’s flight from Bali to Bima will also begin on Monday, December 15.“For the first week, we will operate one scheduled flight from Bali to Bima on Monday, Wednesday, Friday and Sunday.“Starting December 22, TransNusa will operate daily scheduled flights from Bali to Bima,” said Datuk Bernard, adding that the flight will depart Bali from the Denpasar International Airport at 09.35am and arrive at 10.35am at the Sultan Muhammad Salahuddin Airport in Bima.The return flight will depart Bima’s Sultan Muhammad Salahuddin Airport at 11.00am and arrive at Bali’s Denpasar International Airport at 12.10pm.Meanwhile, TransNusa’s schedule flight from Sorong to Timika will operate four times weekly on Monday, Tuesday, Thursday and Saturday.The flight, which will also begin on December 15, will depart Sorong from the Domine Eduard Osok International Airport at 10.50am and arrive in Timika’s Mozes Kilangin Airport at 12.10pm. The return flight will depart Timika at 12.40pm and arrive in Sorong at 14.00pm.On the much sought-after Manado-Sorong route, Datuk Bernard said that TransNusa’s will operate its scheduled flight from Manado to Sorong four times weekly.The scheduled flight from diving haven Manado will operate on Monday, Tuesday, Thursday and Saturday. The flight will depart Manado’s Sam Ratulangi International AIrport at 08.00am and arrive in Sorong’s Domine Eduard Osok International Airport at 10.20am. The return flight will depart Sorong at 14.30pm and arrive in Manado at 14.50pm.TransNusa, A Short HistoryThe 3-year old TransNusa, led by aviation expert and veteran, Datuk Bernard, made waves in the aviation industry with its unique domestic and international business development and growth strategy.Within just 6 months of operations, in 2023, the airline, known then as a new player with new rules, launched its first international route between Jakarta and Kuala Lumpur, followed by the launch of scheduled flights between Jakarta and Singapore.TransNusa, which established itself as a Premium Service Carrier, made headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia to introduce new exciting routes. In 2023, during its first year of operations, TransNusa became the second Indonesian airline to receive approval to fly to China. In 2024, TransNusa became the first in the world to develop and introduce a new domestic route connecting Bali and Manado. In October 2025, TransNusa added yet another milestones by becoming the first Indonesian airline and second airline in the world to launch scheduled flights from Manado to Guangzhou, China.Media Contact:Trina Thomas RajMobile: +6012 4992672E-mail: trina@myqaseh.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月15日 - (亞太商訊 via SeaPRwire.com) - 12月12日，華芢生物-B(02396.HK)正式開啟招股，公司擬全球發售1764.88萬股股份，其中香港發售股份176.50萬股，國際發售股份1588.38萬股，附帶264.72萬股超額配股權，招股期至12月17日，最高發售價51.00港元，中國生物制藥領域也將迎來重磅IPO。據悉，華芢生物深耕傷口癒合領域，在糖尿病足（糖足）領域取得突破性進展，精准卡位老齡化及糖尿病年輕化萬億級剛需市場。依託青島高科（嶗山區財政局全資控股的國資平台）的產業資源整合能力與政策協同優勢，疊加自主搭建的"蛋白+核酸"雙技術平台及覆蓋14個適應症的差異化管線佈局，以及行業頂尖高管團隊加持，為港股市場投資者構築起抵禦18A生物科技企業高風險的安全邊際。市場普遍將其視為繼寶濟藥業之後又一具備高成長潛力的港股18A標的——不僅擁有扎實的臨床進展和清晰的商業化路徑，更兼具稀缺性與確定性，有望成為下一個被資本市場深度挖掘的價值明星。銀髮浪潮疊加年輕化趨勢：糖足治療剛需市場再擴容據國家統計局數據，全國60周歲及以上人口達3.1億（占總人口22.0%），其中65歲以上人群占比突破15.6%。老齡化加速催生糖尿病防控壓力，而與此同時，糖尿病年輕化趨勢正進一步擴大患者基數，形成"銀髮群體為主、青年群體補充"的雙重市場增量。弗若斯特沙利文報告顯示，我國糖尿病患者約1.4億，四分之一的糖尿病患者會在某個階段發展為糖足，2024年中國的糖足患病人數為840萬人。而當前GLP-1類減肥藥（如司美格魯肽）因減重效果顯著成為"網紅神藥"，但其作用機制聚焦於抑制食欲與延緩胃排空，對糖足等血管神經病變類併發症無實質改善。與此同時，術後傷口癒合市場規模同樣超千億，傳統治療手段痛點顯著。在糖足治療領域，已從傳統外科清創轉向生物製劑主導的精准修復時代。中國糖足患者基數龐大，傳統療法（清創+抗生素）因無法解決血管神經病變導致的慢性創面修復障礙，臨床癒合率長期低於50%。PDGF（血小板衍生生長因數）類藥物憑藉其獨特的"血管新生-組織修復"雙效機制，能夠特異性啟動特定受體，促進成纖維細胞增殖與毛細血管生成，顯著加速創面癒合進程，成為千億級慢病管理與術後修復賽道的重磅增長引擎。華芢生物正是瞄準這一藍海市場，向"港股PDGF第一股"發起衝擊。技術突破+醫保減負：核心產品創造多重價值即便處於高研發投入期，華芢生物仍通過自主研發實現關鍵突破——優化核心技術序列並革新生產工藝，構建起差異化競爭優勢。其核心產品Pro-101-1的IIa期數據顯示，可使淺/深二度燒傷癒合時間縮短約7天，較傳統療法效率提升25%，這一突破為患者、醫療體系與醫保基金創造多重價值。對糖足及燒傷患者而言，癒合時間縮短能直接減少住院時長與家庭護理成本，降低因術後恢復導致的誤工、護理人員誤工等間接經濟損失，堪稱"糖尿病足患者的福音"；對醫療體系來說，患者住院週期縮短可提高病床周轉率，減少醫療資源佔用，緩解醫護人員工作壓力；對醫保基金而言，治療週期縮短與再治療需求降低，能有效減輕醫保支出負擔，契合當前醫療保障體系降本增效的核心訴求。從技術平台來看，華芢生物以自主搭建的蛋白質藥物技術平台為核心，形成"蛋白+核酸"雙輪創新架構：酵母表達系統通過工藝革新提升蛋白生產效率，雙引擎協同支撐燒傷修復、糖尿病足潰瘍、脫髮治療等核心產品的臨床轉化，同時展現出向腫瘤疫苗、罕見病領域延展的技術潛力，為長期發展奠定技術基礎。國資托底+高管賦能+頂尖平台+強力護航：四重保障化解研發與市場風險生物制藥的研發向來充滿不確定性，一款新藥從實驗室到上市往往九死一生。但在華芢生物這裏，這種風險似乎被巧妙地拆解成了可控變數。在股權與資源端，青島高科產業發展有限公司（嶗山區財政局全資控股的國資平台）作為核心股東，通過持股17.32%（全球發售後相關類別股份）形成長期綁定，其國資屬性為公司在地方醫療資源對接、政策協調中奠定信任基礎，成為連接區域產業生態與研發管線的關鍵紐帶。在管理端，公司獲MNC大廠高管賦能，迎來兩位行業頂尖人才加盟，進一步強化創新發展底氣。其中，苗天祥先生曾是"外資藥企中國掌門人"代表，擁有近30年輝瑞中國工作經歷，曾任輝瑞中國大中華區主席，在財務、企業管理及制藥行業積累深厚經驗，現任華芢生物執行董事兼首席戰略官，負責制定、實施和監督公司整體戰略規劃，為企業把握行業方向、推進研發與市場佈局提供關鍵指導；宋冰女士曾長期任職於頂尖國際投行高盛高華證券，擔任總經理兼首席運營官，在金融投資、企業戰略及資本運作領域具備極強創造力與領導力，現任公司監事會主席，為整體規劃提供建議與監督，助力優化資源整合、提升資本運作效率。兩位核心高管的"組合賦能"，與研發團隊技術創新形成合力，讓華芢生物在PDGF藥物研發與市場拓展中具備獨特優勢。在資本端，本次IPO由中信證券擔任聯席保薦人。值得一提的是，中信證券2025年在港股18A生物科技IPO領域表現亮眼，其保薦的其中7個專案均實現首日未破發，映恩生物、勁方醫藥等專案首日漲幅超100%，12月10日掛牌的寶濟藥業更錄得3526.34倍公開發售認購、暗盤一度暴漲超115%的佳績，中慧生物、旺山旺水也分別創下4007.64倍、6238.42倍的超高認購，充分獲得機構及專業投資者認可，為後續二級市場投資者提供堅實信心支撐。在管線端，公司"階梯式"研發管線進一步降低風險。目前，用於治療深二度燒燙傷的產品Pro-101-1，已完成IIb期臨床試驗的統計數據分析，用於治療淺二度燒燙傷的，已完成最後一例患者出組；用於治療糖尿病足潰瘍（糖足）的產品Pro-101-2正處於II期臨床試驗階段。未來，PDGF也有望應用於普通外科、牙科、皮膚科等近20個適應症。就連看似"跨界"的脫髮微針產品Pro-104，也已規劃在2029年提交IND申請。這種"成熟產品貢獻現金流、在研管線儲備未來"的佈局，像極了跨國藥企的經典打法——即便某一管線受挫，也不至於動搖根基。稀缺標的+港股通預期：投資者的優質選擇從市場屬性來看，華芢生物是"小而美"的稀缺標的，當前發行規模適中，流通盤較小，疊加清晰的盈利路徑與高壁壘技術平台，使其具備極強的流動性溢價潛力。市場普遍預期其在滿足市值與流動性條件後有望快速納入港股通，吸引南向資金配置，進一步放大賺錢效應。儘管近期港股市場有6支新股同步發售，資金面承壓，但華芢生物憑藉其純正的18A生物科技屬性，明確的臨床里程碑及國資背景與高管優勢，在年末IPO窗口中脫穎而出。對投資者而言，"國資背書+技術平台+管線梯隊+高管賦能"的組合，讓風險更可量化，契合長期資本對確定性增長的需求。在老齡化加速與創新藥政策紅利共振下，華芢生物以"癒合剛需+技術壁壘+國資護航+高管賦能"構建起獨特價值座標。對於尋求確定性增長的長期資本而言，這家即將登陸港交所的生物制藥新星，或將成為對沖行業波動、捕捉結構性機會的優質標的。其扎實技術與管線積澱更將為港股創新藥板塊注入新動能，推動PDGF藥物行業創新升級，專業投資市場亦在期待其更長期的價值兌現。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com